Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Omar A. Abdul-Rahman is active.

Publication


Featured researches published by Omar A. Abdul-Rahman.


Pediatrics | 2014

Prevalence and Characteristics of Fetal Alcohol Spectrum Disorders

Philip A. May; Amy Baete; Jaymi Russo; Amy J. Elliott; Jason Blankenship; Wendy O. Kalberg; David Buckley; Marita Brooks; Julie M. Hasken; Omar A. Abdul-Rahman; Adam Mp; Luther K. Robinson; Melanie A. Manning; H. Eugene Hoyme

OBJECTIVES: To determine the prevalence and characteristics of fetal alcohol spectrum disorders (FASD) among first grade students (6- to 7-year-olds) in a representative Midwestern US community. METHODS: From a consented sample of 70.5% of all first graders enrolled in public and private schools, an oversample of small children (≤25th percentile on height, weight, and head circumference) and randomly selected control candidates were examined for physical growth, development, dysmorphology, cognition, and behavior. The children’s mothers were interviewed for maternal risk. RESULTS: Total dysmorphology scores differentiate significantly fetal alcohol syndrome (FAS) and partial FAS (PFAS) from one another and from unexposed controls. Alcohol-related neurodevelopmental disorder (ARND) is not as clearly differentiated from controls. Children who had FASD performed, on average, significantly worse on 7 cognitive and behavioral tests and measures. The most predictive maternal risk variables in this community are late recognition of pregnancy, quantity of alcoholic drinks consumed 3 months before pregnancy, and quantity of drinking reported for the index child’s father. From the final multidisciplinary case findings, 3 techniques were used to estimate prevalence. FAS in this community likely ranges from 6 to 9 per 1000 children (midpoint, 7.5), PFAS from 11 to 17 per 1000 children (midpoint, 14), and the total rate of FASD is estimated at 24 to 48 per 1000 children, or 2.4% to 4.8% (midpoint, 3.6%). CONCLUSIONS: Children who have FASD are more prevalent among first graders in this Midwestern city than predicted by previous, popular estimates.


Nature Genetics | 2012

De novo mutations in the actin genes ACTB and ACTG1 cause Baraitser-Winter syndrome

Jean-Baptiste Rivière; Bregje W.M. van Bon; Alexander Hoischen; Stanislav Kholmanskikh; Brian J. O'Roak; Christian Gilissen; Sabine J. Gijsen; Christopher T. Sullivan; Susan L. Christian; Omar A. Abdul-Rahman; Joan F. Atkin; Nicolas Chassaing; Valérie Drouin-Garraud; Andrew E. Fry; Jean-Pierre Fryns; Karen W. Gripp; Marlies Kempers; Tjitske Kleefstra; Grazia M.S. Mancini; Małgorzata J.M. Nowaczyk; Conny M. A. van Ravenswaaij-Arts; Tony Roscioli; Michael Marble; Jill A. Rosenfeld; Victoria M. Siu; Bert B.A. de Vries; Jay Shendure; Alain Verloes; Joris A. Veltman; Han G. Brunner

Brain malformations are individually rare but collectively common causes of developmental disabilities. Many forms of malformation occur sporadically and are associated with reduced reproductive fitness, pointing to a causative role for de novo mutations. Here, we report a study of Baraitser-Winter syndrome, a well-defined disorder characterized by distinct craniofacial features, ocular colobomata and neuronal migration defect. Using whole-exome sequencing of three proband-parent trios, we identified de novo missense changes in the cytoplasmic actin–encoding genes ACTB and ACTG1 in one and two probands, respectively. Sequencing of both genes in 15 additional affected individuals identified disease-causing mutations in all probands, including two recurrent de novo alterations (ACTB, encoding p.Arg196His, and ACTG1, encoding p.Ser155Phe). Our results confirm that trio-based exome sequencing is a powerful approach to discover genes causing sporadic developmental disorders, emphasize the overlapping roles of cytoplasmic actin proteins in development and suggest that Baraitser-Winter syndrome is the predominant phenotype associated with mutation of these two genes.


Nature Genetics | 2012

Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome

Jeroen Van Houdt; Beata Nowakowska; Sérgio B. de Sousa; Barbera D. C. van Schaik; Eve Seuntjens; Nelson Avonce; Alejandro Sifrim; Omar A. Abdul-Rahman; Marie Jose H. van den Boogaard; Armand Bottani; Marco Castori; Valérie Cormier-Daire; Matthew A. Deardorff; Isabel Filges; Alan Fryer; Jean Pierre Fryns; Simone Gana; Livia Garavelli; Gabriele Gillessen-Kaesbach; Bryan D. Hall; Denise Horn; Danny Huylebroeck; Jakub Klapecki; Małgorzata Krajewska-Walasek; Alma Kuechler; Saskia M. Maas; Kay D. MacDermot; Shane McKee; Alex Magee; Stella A. de Man

Nicolaides-Baraitser syndrome (NBS) is characterized by sparse hair, distinctive facial morphology, distal-limb anomalies and intellectual disability. We sequenced the exomes of ten individuals with NBS and identified heterozygous variants in SMARCA2 in eight of them. Extended molecular screening identified nonsynonymous SMARCA2 mutations in 36 of 44 individuals with NBS; these mutations were confirmed to be de novo when parental samples were available. SMARCA2 encodes the core catalytic unit of the SWI/SNF ATP-dependent chromatin remodeling complex that is involved in the regulation of gene transcription. The mutations cluster within sequences that encode ultra-conserved motifs in the catalytic ATPase region of the protein. These alterations likely do not impair SWI/SNF complex assembly but may be associated with disrupted ATPase activity. The identification of SMARCA2 mutations in humans provides insight into the function of the Snf2 helicase family.


Pediatrics | 2016

Updated clinical guidelines for diagnosing fetal alcohol spectrum disorders

H. Eugene Hoyme; Wendy O. Kalberg; Amy J. Elliott; Jason Blankenship; David Buckley; Anna Susan Marais; Melanie A. Manning; Luther K. Robinson; Adam Mp; Omar A. Abdul-Rahman; Tamison Jewett; Claire D. Coles; Christina D. Chambers; Kenneth Lyons Jones; Colleen M. Adnams; Prachi E. Shah; Edward P. Riley; Michael E. Charness; Kenneth R. Warren; Philip A. May

The adverse effects of prenatal alcohol exposure constitute a continuum of disabilities (fetal alcohol spectrum disorders [FASD]). In 1996, the Institute of Medicine established diagnostic categories delineating the spectrum but not specifying clinical criteria by which diagnoses could be assigned. In 2005, the authors published practical guidelines operationalizing the Institute of Medicine categories, allowing for standardization of FASD diagnoses in clinical settings. The purpose of the current report is to present updated diagnostic guidelines based on a thorough review of the literature and the authors’ combined expertise based on the evaluation of >10 000 children for potential FASD in clinical settings and in epidemiologic studies in conjunction with National Institute on Alcohol Abuse and Alcoholism–funded studies, the Collaborative Initiative on Fetal Alcohol Spectrum Disorders, and the Collaboration on FASD Prevalence. The guidelines were formulated through conference calls and meetings held at National Institute on Alcohol Abuse and Alcoholism offices in Rockville, MD. Specific areas addressed include the following: precise definition of documented prenatal alcohol exposure; neurobehavioral criteria for diagnosis of fetal alcohol syndrome, partial fetal alcohol syndrome, and alcohol-related neurodevelopmental disorder; revised diagnostic criteria for alcohol-related birth defects; an updated comprehensive research dysmorphology scoring system; and a new lip/philtrum guide for the white population, incorporating a 45-degree view. The guidelines reflect consensus among a large and experienced cadre of FASD investigators in the fields of dysmorphology, epidemiology, neurology, psychology, developmental/behavioral pediatrics, and educational diagnostics. Their improved clarity and specificity will guide clinicians in accurate diagnosis of infants and children prenatally exposed to alcohol.


American Journal of Human Genetics | 2012

Mutations in KAT6B, encoding a histone acetyltransferase, cause Genitopatellar syndrome.

Philippe M. Campeau; Jaeseung C. Kim; James T. Lu; Jeremy Schwartzentruber; Omar A. Abdul-Rahman; Silke Schlaubitz; David M. Murdock; Ming-Ming Jiang; Edward J. Lammer; Gregory M. Enns; William J. Rhead; Jon Rowland; Stephen P. Robertson; Valérie Cormier-Daire; Matthew N. Bainbridge; Xiang-Jiao Yang; Marie-Claude Gingras; Richard A. Gibbs; David S. Rosenblatt; Jacek Majewski; Brendan Lee

Genitopatellar syndrome (GPS) is a skeletal dysplasia with cerebral and genital anomalies for which the molecular basis has not yet been determined. By exome sequencing, we found de novo heterozygous truncating mutations in KAT6B (lysine acetyltransferase 6B, formerly known as MYST4 and MORF) in three subjects; then by Sanger sequencing of KAT6B, we found similar mutations in three additional subjects. The mutant transcripts do not undergo nonsense-mediated decay in cells from subjects with GPS. In addition, human pathological analyses and mouse expression studies point to systemic roles of KAT6B in controlling organismal growth and development. Myst4 (the mouse orthologous gene) is expressed in mouse tissues corresponding to those affected by GPS. Phenotypic differences and similarities between GPS, the Say-Barber-Biesecker variant of Ohdo syndrome (caused by different mutations of KAT6B), and Rubinstein-Taybi syndrome (caused by mutations in other histone acetyltransferases) are discussed. Together, the data support an epigenetic dysregulation of the limb, brain, and genital developmental programs.


European Journal of Human Genetics | 2010

Chiari I malformation, delayed gross motor skills, severe speech delay, and epileptiform discharges in a child with FOXP1 haploinsufficiency

Christopher W. Carr; Daniel Moreno-De-Luca; Colette Parker; Holly H. Zimmerman; Nikki Ledbetter; Christa Lese Martin; William B. Dobyns; Omar A. Abdul-Rahman

Human FOXP2 deficiency has been identified as a cause of hereditary developmental verbal dyspraxia. Another member of the same gene family, FOXP1, has expression patterns that overlap with FOXP2 in some areas of the brain, and FOXP1 and FOXP2 have the ability to form heterodimers. These findings suggest the possibility that FOXP1 may also contribute to proper speech development. However, no such role of FOXP1 has been established to date. Recently, a child was reported who presented with a 3p13-14.1 deletion of four genes, including FOXP1, and a constellation of deficits that included speech delay. In this study, we report the case of a patient with a single deletion of FOXP1. This patient presented with speech and motor developmental delays, a Chiari I malformation, and epileptiform discharges. The nature of the speech deficit is different from the primary oromotor verbal dyspraxia found in patients with FOXP2 deficiency. The patients developmental deficits may support a role for FOXP1 in the development of verbal and motor skills.


Human Genetics | 2011

BMP4 loss-of-function mutations in developmental eye disorders including SHORT syndrome

Linda M. Reis; Rebecca C. Tyler; Kala F. Schilter; Omar A. Abdul-Rahman; Jeffrey W. Innis; Beth A. Kozel; Adele Schneider; Tanya Bardakjian; Edward J. Lose; Donna M. Martin; Ulrich Broeckel; Elena V. Semina

BMP4 loss-of-function mutations and deletions have been shown to be associated with ocular, digital, and brain anomalies, but due to the paucity of these reports, the full phenotypic spectrum of human BMP4 mutations is not clear. We screened 133 patients with a variety of ocular disorders for BMP4 coding region mutations or genomic deletions. BMP4 deletions were detected in two patients: a patient affected with SHORT syndrome and a patient with anterior segment anomalies along with craniofacial dysmorphism and cognitive impairment. In addition to this, three intragenic BMP4 mutations were identified. A patient with anophthalmia, microphthalmia with sclerocornea, right-sided diaphragmatic hernia, and hydrocephalus was found to have a c.592C>T (p.R198X) nonsense mutation in BMP4. A frameshift mutation, c.171dupC (p.E58RfsX17), was identified in two half-siblings with anophthalmia/microphthalmia, discordant developmental delay/postaxial polydactyly, and poor growth as well as their unaffected mother; one affected sibling carried an additional BMP4 mutation in the second allele, c.362A>G (p.H121R). This is the first report indicating a role for BMP4 in SHORT syndrome, Axenfeld–Rieger malformation, growth delay, macrocephaly, and diaphragmatic hernia. These results significantly expand the number of reported loss-of-function mutations, further support the critical role of BMP4 in ocular development, and provide additional evidence of variable expression/non-penetrance of BMP4 mutations.


Nature Genetics | 2015

Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder

Alexander J. Abrams; Robert B. Hufnagel; Adriana P. Rebelo; Claudia Zanna; Neville Patel; Michael Gonzalez; Ion J. Campeanu; Laurie B. Griffin; Saskia Groenewald; Alleene V. Strickland; Feifei Tao; Fiorella Speziani; Lisa Abreu; Rebecca Schüle; Leonardo Caporali; Chiara La Morgia; Alessandra Maresca; Rocco Liguori; Raffaele Lodi; Zubair M. Ahmed; Kristen L. Sund; Xinjian Wang; Laura A. Krueger; Yanyan Peng; Carlos E. Prada; Cynthia A. Prows; Elizabeth K. Schorry; Anthony Antonellis; Holly H. Zimmerman; Omar A. Abdul-Rahman

Dominant optic atrophy (DOA) and axonal peripheral neuropathy (Charcot-Marie-Tooth type 2, or CMT2) are hereditary neurodegenerative disorders most commonly caused by mutations in the canonical mitochondrial fusion genes OPA1 and MFN2, respectively. In yeast, homologs of OPA1 (Mgm1) and MFN2 (Fzo1) work in concert with Ugo1, for which no human equivalent has been identified thus far. By whole-exome sequencing of patients with optic atrophy and CMT2, we identified four families with recessive mutations in SLC25A46. We demonstrate that SLC25A46, like Ugo1, is a modified carrier protein that has been recruited to the outer mitochondrial membrane and interacts with the inner membrane remodeling protein mitofilin (Fcj1). Loss of function in cultured cells and in zebrafish unexpectedly leads to increased mitochondrial connectivity, while severely affecting the development and maintenance of neurons in the fish. The discovery of SLC25A46 strengthens the genetic overlap between optic atrophy and CMT2 while exemplifying a new class of modified solute transporters linked to mitochondrial dynamics.


American Journal of Medical Genetics Part A | 2013

FOXP1 mutations cause intellectual disability and a recognizable phenotype

Anna Le Fevre; Sharelle Taylor; Neva H. Malek; Denise Horn; Christopher W. Carr; Omar A. Abdul-Rahman; Sherindan O'Donnell; Trent Burgess; Marie Shaw; Jozef Gecz; Nicole Bain; Kerry Fagan; Matthew Hunter

Mutations in FOXP1, located at 3p13, have been reported in patients with global developmental delay (GDD), intellectual disability (ID), and speech defects. Mutations in FOXP2, located at 7q31, are well known to cause developmental speech and language disorders, particularly developmental verbal dyspraxia (DVD). FOXP2 has been shown to work co‐operatively with FOXP1 in mouse development. An overlap in FOXP1 and FOXP2 expression, both in the songbird and human fetal brain, has suggested that FOXP1 may also have a role in speech and language disorders. We report on a male child with a 0.19 MB intragenic deletion that is predicted to result in haploinsufficiency of FOXP1. Review of our patient and others reported in the literature reveals an emerging phenotype of GDD/ID with moderate to severe speech delay where expressive speech is most severely affected. DVD appears not to be a distinct feature in this group. Facial features include a broad forehead, downslanting palpebral fissures, a short nose with broad tip, relative or true macrocephaly, a frontal hair upsweep and prominent digit pads. Autistic traits and other behavioral problems are likely to be associated with haploinsufficiency of FOXP1. Congenital malformations may be associated.


Journal of Medical Genetics | 2013

Phenotype and genotype in 101 males with X-linked creatine transporter deficiency

J.M. van de Kamp; Ofir T. Betsalel; Saadet Mercimek-Mahmutoglu; L Abulhoul; S Grünewald; Irina Anselm; H Azzouz; Drago Bratkovic; A.P.M. de Brouwer; B.C.J. Hamel; Tjitske Kleefstra; Helger G. Yntema; Jaume Campistol; M. A. Vilaseca; D. Cheillan; M D'Hooghe; Luísa Diogo; Paula Garcia; Carla Valongo; M Fonseca; Suzanna G M Frints; Bridget Wilcken; S von der Haar; Hanne Meijers-Heijboer; F Hofstede; D Johnson; Sarina G. Kant; L. Lion-François; Gaëlle Pitelet; Nicola Longo

Background Creatine transporter deficiency is a monogenic cause of X-linked intellectual disability. Since its first description in 2001 several case reports have been published but an overview of phenotype, genotype and phenotype–genotype correlation has been lacking. Methods We performed a retrospective study of clinical, biochemical and molecular genetic data of 101 males with X-linked creatine transporter deficiency from 85 families with a pathogenic mutation in the creatine transporter gene (SLC6A8). Results and conclusions Most patients developed moderate to severe intellectual disability; mild intellectual disability was rare in adult patients. Speech language development was especially delayed but almost a third of the patients were able to speak in sentences. Besides behavioural problems and seizures, mild to moderate motor dysfunction, including extrapyramidal movement abnormalities, and gastrointestinal problems were frequent clinical features. Urinary creatine to creatinine ratio proved to be a reliable screening method besides MR spectroscopy, molecular genetic testing and creatine uptake studies, allowing definition of diagnostic guidelines. A third of patients had a de novo mutation in the SLC6A8 gene. Mothers with an affected son with a de novo mutation should be counselled about a recurrence risk in further pregnancies due to the possibility of low level somatic or germline mosaicism. Missense mutations with residual activity might be associated with a milder phenotype and large deletions extending beyond the 3′ end of the SLC6A8 gene with a more severe phenotype. Evaluation of the biochemical phenotype revealed unexpected high creatine levels in cerebrospinal fluid suggesting that the brain is able to synthesise creatine and that the cerebral creatine deficiency is caused by a defect in the reuptake of creatine within the neurones.

Collaboration


Dive into the Omar A. Abdul-Rahman's collaboration.

Top Co-Authors

Avatar

Holly H. Zimmerman

University of Mississippi Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adam Mp

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Christopher W. Carr

University of Mississippi Medical Center

View shared research outputs
Top Co-Authors

Avatar

Elena V. Semina

Children's Hospital of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

H. Eugene Hoyme

University of South Dakota

View shared research outputs
Top Co-Authors

Avatar

Linda M. Reis

Medical College of Wisconsin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Philip A. May

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge